{{Rsnum
|rsid=2303500
|Gene=FBN1
|Chromosome=15
|position=48447077
|Orientation=minus
|GMAF=0.3632
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FBN1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 57.5 | 35.4 | 7.1
| HCB | 36.5 | 49.6 | 13.9
| JPT | 27.4 | 46.9 | 25.7
| YRI | 19.0 | 52.4 | 28.6
| ASW | 12.3 | 54.4 | 33.3
| CHB | 36.5 | 49.6 | 13.9
| CHD | 37.6 | 45.0 | 17.4
| GIH | 55.4 | 34.7 | 9.9
| LWK | 18.2 | 50.9 | 30.9
| MEX | 70.7 | 20.7 | 8.6
| MKK | 30.8 | 50.6 | 18.6
| TSI | 58.8 | 37.3 | 3.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2303500
|Name_s=
|Gene_s=FBN1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109378
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2303500
|overall_frequency_n=79
|overall_frequency_d=128
|overall_frequency=0.617188
|n_genomes=44
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}